Embecta

Embecta Pretax Income

The Pretax Income (EBT) of Embecta (EMBC) as of Nov 2, 2026 is 136.30 M USD. In the previous year, Pretax Income (EBT) was 44.20 M USD — a change of 208.37% (higher).

Pretax Income

136.30 MUSD

YoY

208.37%

Last updated:

Pretax Income (EBT) of Embecta is 2025 136.30 M USD. Pretax Income (EBT) of Embecta was 2024 44.20 M USD. It decreases by 208.37% higher compared to the previous year.

The Embecta Pretax Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pretax Income
Date
Pretax Income
Jan 1, 2019
500.00 M USD
Jan 1, 2020
485.80 M USD
Jan 1, 2021
495.00 M USD
Jan 1, 2022
256.60 M USD
Jan 1, 2023
105.70 M USD
Jan 1, 2024
44.20 M USD
Jan 1, 2025
136.30 M USD
The Embecta Pretax Income history
YEARPretax IncomeYoY
136.30 MUSD+208.37%
44.20 MUSD-58.18%
105.70 MUSD-58.81%
256.60 MUSD-48.16%
495.00 MUSD+1.89%
485.80 MUSD-2.84%
500.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Pretax Income (EBT) of Embecta is 136.30 M USD in 2025.

Pretax Income (EBT) of Embecta changed from 44.20 M USD to 136.30 M USD, representing a 208.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pretax Income (EBT) Embecta since 2006 – with annual values, charts, and detailed analysis.

Pretax income represents earnings before income taxes. It shows a company's profitability independent of tax strategies.

Pretax Income (EBT)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Pretax Income (EBT)'s Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Embecta

All Key Metrics — Embecta